Carboat, you don't understand SOC. Even when a drug shows a stat. sig. survival benefit, like Ramucirumab did in 2nd line NSCLC, it doesn't magically become SOC. The benefit needs to justify the AE profile and the cost, which is especially important in the UK. If PPHM is actually on track to finish enrollment this December, I doubt this Opdivo trial data will be more than another Ramu "meh" when the veil is lifted on the full data set.
News 
Market Data 
Discover 
